secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akari Therapeutics Plc (AKTX)
CIK:        0001541157
Form:       8-K/A
Filed at:   2024-08-23T23:59:59+00:00
Accession:  0000950170-24-100211
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Akari Therapeutics discloses CEO separation terms: $450K payment, RSU vesting/forfeiture
--------------------------------------------------------------------------------

- Rachelle Jacques stepped down as President and CEO effective May 1, 2024.
- Separation agreement on Aug 19, 2024 provides $450K lump sum payment contingent on merger close or by Dec 2, 2024.
- Vesting of RSUs representing 276M ordinary shares; forfeiture of RSUs representing 482.25M ordinary shares.
- Payment condition tied to anticipated merger with Peak Bio, Inc.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1541157/000095017024100211/0000950170-24-100211-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1541157/000095017024100211/aktx-20240425.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-100211

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer